【Tech 24H】The 17th China Bioindustry Convention opened in Wuhan on September 4, showcasing the latest achievements from bio-industry bases, research institutions, and leading enterprises worldwide. Among the groundbreaking innovations presented was the world’s first plant-derived recombinant human albumin injection, developed by Wuhan Healthgen Biotech. As the first Class I new drug utilizing "rice-based blood production," it has already been applied in patient treatments, eliminating the historical reliance on plasma extraction for human serum albumin. Tongji Hospital exhibited an optical brain-computer interface, pioneering a multimodal sensing system integrating electroencephalogram and near infrared spectrum for cerebral hemorrhage rehabilitation, expected to launch next year. Additionally, Wuhan Binhui Bio introduced OH2 Injection, the world’s first oncolytic virus candidate drug based on Type II herpes simplex virus to enter clinical studies.